The Head of the Federal Medical and Biological Agency (FMBA) of Russia, Veronika Skvortsova, announced that her agency is planning to launch four new drugs by 2026 to treat orphan diseases. She mentioned the following drugs for treating different medical conditions: “Ataluren” for muscular dystrophy, “Selexipag” for pulmonary arterial hypertension, “Teduglutide” for short bowel syndrome, and “Tricafta” for cystic fibrosis.
At the conference, Tatyana Yakovleva, the first deputy head of the FMBA of Russia, announced that clinical studies of the allergen vaccine developed by FMBA specialists are scheduled to commence in the fall of 2024.
The director of the State Research Center “Institute of Immunology” of the Federal Medical and Biological Agency of Russia, Musa Khaitov, has announced that the agency’s employees are currently developing a new cytokine drug for the treatment of bronchial asthma, which is expected to be available within three to four years.
